Molecular Templates, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13 nov. 2018 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
09 nov. 2018 08h00 HE
|
Molecular Templates, Inc.
Antigen Seeding Technology (AST) is a Potent and Complimentary Addition to Company’s Engineered Toxin Bodies (ETB) Technology AUSTIN, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates,...
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Healthcare Conferences
26 sept. 2018 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary...
Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares
25 sept. 2018 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary...
Molecular Templates, Inc. Announces Pricing of Public Offering of Common Stock
20 sept. 2018 20h41 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary...
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
19 sept. 2018 16h01 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage oncology company focused on the discovery and development...
Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy
19 sept. 2018 08h00 HE
|
Molecular Templates, Inc.
The Agreement Will Support the Development of a Potential New Treatment Option for Multiple Myeloma AUSTIN, Texas, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) today...
Molecular Templates, Inc. Reports Second Quarter 2018 Financial Results
09 août 2018 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and...
Molecular Templates Set to Join the Russell 3000® and Russell Microcap® Indexes
21 juin 2018 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, June 21, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin...
Molecular Templates Presents Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018
04 juin 2018 16h30 HE
|
Molecular Templates, Inc.
ASCO Posters Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas, June 04, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM), a clinical stage biopharmaceutical company focused on...